In conclusion, the PRR antagonist, PRO20, ameliorates HFD-induced fatty liver development in mice, whereas losartan, an AT1R blocker, does not attenuate the development of hepatic steatosis in HFD-fed mice, suggesting that the effect of PRR antagonism in hepatic steatosis is RAS-independent. This evidence concerns the gene AGTR1 and fatty liver disease.